Mealey's (February 5, 2019, 12:35 PM EST) -- SANTA ANA, Calif. — A federal jury in California on Feb. 4 handed down a rare verdict in favor of investors on one of four alleged misrepresentations in a securities class action lawsuit claiming that a drug company and its CEO misrepresented the effectiveness of the drug company’s breast cancer treatment drug in violation of federal securities laws (Hsingching Hsu v. Puma Biotechnology Inc., et al., No. 15-0865, C.D. Calif., 2017 U.S. Dist. LEXIS 206236)....